4.5 Review

Gut hormones: the future of obesity treatment?

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 74, Issue 6, Pages 911-919

Publisher

WILEY
DOI: 10.1111/j.1365-2125.2012.04278.x

Keywords

glucagon-like peptide-1; gut hormones; obesity; oxyntomodulin; pancreatic polypeptide; peptide YY

Funding

  1. BBSRC [BB/I001816/1, BB/E52708X/1] Funding Source: UKRI
  2. Biotechnology and Biological Sciences Research Council [BB/I001816/1, BB/E52708X/1] Funding Source: Medline
  3. Biotechnology and Biological Sciences Research Council [BB/E52708X/1, BB/I001816/1] Funding Source: researchfish

Ask authors/readers for more resources

Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available